Despite potential sympathetic adverse effects, one MC4R agonist emerging therapy undergoing clinical trials for treating generalized non-diseased obesity called RM-493 (Clinicaltrials.gov ID: NCT02041195; Clinicaltrials.gov ID: NCT01749137). Here, MC4R is linked to obesity disorder.